source
- #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotThe molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…Endpoints · 2mo ago↗ source
- STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsJohnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.STAT · 2mo ago↗ source
- Major readouts from the annual diabetes conferenceWhy "Schedule F" matters, the Ebola outbreak response, and more health news from Morning RoundsSTAT · 2mo ago↗ source